Article

Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor α–Mediated Ceramide De novo Synthesis in Colon Cancer Cells

Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy.
Clinical Cancer Research (Impact Factor: 8.19). 01/2009; 14(23):7691-700. DOI: 10.1158/1078-0432.CCR-08-0799
Source: PubMed

ABSTRACT Cannabinoids have been recently proposed as a new family of potential antitumor agents. The present study was undertaken to investigate the expression of the two cannabinoid receptors, CB1 and CB2, in colorectal cancer and to provide new insight into the molecular pathways underlying the apoptotic activity induced by their activation.
Cannabinoid receptor expression was investigated in both human cancer specimens and in the DLD-1 and HT29 colon cancer cell lines. The effects of the CB1 agonist arachinodyl-2'-chloroethylamide and the CB2 agonist N-cyclopentyl-7-methyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide (CB13) on tumor cell apoptosis and ceramide and tumor necrosis factor (TNF)-alpha production were evaluated. The knockdown of TNF-alpha mRNA was obtained with the use of selective small interfering RNA.
We show that the CB1 receptor was mainly expressed in human normal colonic epithelium whereas tumor tissue was strongly positive for the CB2 receptor. The activation of the CB1 and, more efficiently, of the CB2 receptors induced apoptosis and increased ceramide levels in the DLD-1 and HT29 cells. Apoptosis was prevented by the pharmacologic inhibition of ceramide de novo synthesis. The CB2 agonist CB13 also reduced the growth of DLD-1 cells in a mouse model of colon cancer. The knockdown of TNF-alpha mRNA abrogated the ceramide increase and, therefore, the apoptotic effect induced by cannabinoid receptor activation.
The present study shows that either CB1 or CB2 receptor activation induces apoptosis through ceramide de novo synthesis in colon cancer cells. Our data unveiled, for the first time, that TNF-alpha acts as a link between cannabinoid receptor activation and ceramide production.

Download full-text

Full-text

Available from: Matteo Lulli, Aug 29, 2015
0 Followers
 · 
230 Views
  • Source
    • "tumour growth in AOM - induced colitis - associated colon cancer ( Kargl et al . 2013 ) . In the xenograft model of colon cancer , semi - synthetic cannabinoids such as the cannabinoid quinone HU - 331 and the hexahydrocannabinol ana - logue LYR - 8 ( Thapa et al . 2012 ; Kogan et al . 2007 ) , as well as the selective CB 2 receptor agonist CB13 ( Cianchi et al . 2008"
    [Show abstract] [Hide abstract]
    ABSTRACT: Colon cancer is a major public health problem. Cannabis-based medicines are useful adjunctive treatments in cancer patients. Here, we have investigated the effect of a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here named CBD BDS, i.e. CBD botanical drug substance, on colorectal cancer cell proliferation and in experimental models of colon cancer in vivo. Proliferation was evaluated in colorectal carcinoma (DLD-1 and HCT116) as well as in healthy colonic cells using the MTT assay. CBD BDS binding was evaluated by its ability to displace [(3)H]CP55940 from human cannabinoid CB1 and CB2 receptors. In vivo, the effect of CBD BDS was examined on the preneoplastic lesions (aberrant crypt foci), polyps and tumours induced by the carcinogenic agent azoxymethane (AOM) as well as in a xenograft model of colon cancer in mice. CBD BDS and CBD reduced cell proliferation in tumoral, but not in healthy, cells. The effect of CBD BDS was counteracted by selective CB1 and CB2 receptor antagonists. Pure CBD reduced cell proliferation in a CB1-sensitive antagonist manner only. In binding assays, CBD BDS showed greater affinity than pure CBD for both CB1 and CB2 receptors, with pure CBD having very little affinity. In vivo, CBD BDS reduced AOM-induced preneoplastic lesions and polyps as well as tumour growth in the xenograft model of colon cancer. CBD BDS attenuates colon carcinogenesis and inhibits colorectal cancer cell proliferation via CB1 and CB2 receptor activation. The results may have some clinical relevance for the use of Cannabis-based medicines in cancer patients.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 12/2013; 21. DOI:10.1016/j.phymed.2013.11.006 · 2.88 Impact Factor
  • Source
    • "The main active ingredient of cannabis, Δ 9 -tetrahydrocannabinol (Δ 9 -THC), mediates its effects through binding and activation of CB1 [5–7] and/or CB2 receptors [8, 9]. Because THC and its analogues have been used in palliative treatments where they inhibit tumour cell growth [10], research dedicated to the potential role of THC and the modulation of the endocannabinoid system in cancer treatment has increased [10] [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The "endocannabinoid system (ECS)" comprises the endocannabinoids, the enzymes that regulate their synthesis and degradation, the prototypical cannabinoid receptors (CB1 and CB2), some noncannabinoid receptors, and an, as yet, uncharacterised transport system. Recent evidence suggests that both cannabinoid receptors are present in sex steroid hormone-dependent cancer tissues and potentially play an important role in those malignancies. Sex steroid hormones regulate the endocannabinoid system and the endocannabinoids prevent tumour development through putative protective mechanisms that prevent cell growth and migration, suggesting an important role for endocannabinoids in the regulation of sex hormone-dependent tumours and metastasis. Here, the role of the endocannabinoid system in sex steroid hormone-dependent cancers is described and the potential for novel therapies assessed.
    International Journal of Endocrinology 11/2013; 2013:259676. DOI:10.1155/2013/259676 · 1.52 Impact Factor
  • Source
    • "Some of these compounds showed pharmacological properties like inhibitory action on immunological human basophil activation (Manera et al. 2006, 2009), anti-proliferative activity (Manera et al. 2012) and we recently demonstrated their effects on immune cells isolated from multiple sclerosis patients (Malfitano et al. 2013). Furthermore, the CB2 agonist CB13 reduced the growth of DLD-1 cells in a mouse model of colon cancer inducing apoptosis (Cianchi et al. 2008) and the naphthyridine derivative HLK-1 induces G2/M arrest and mitotic catastrophe in human leukemic HL-60 cells (Hsu et al. 2012). In this study, we tested the potential immunemodulatory and anti-inflammatory effects of the 1,8- naphthyridin-4-one derivatives CB13 and CB82 and 1,8- naphthyridin-2-one derivative CB91 in peripheral blood mononuclear cells (PBMC) isolated from healthy donors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Considering the high selectivity at the cannabinoid CB2 receptor of recently designed 1,8-naphthyridine derivatives and the protective role of this receptor in neurological disorders, in this study we investigated the immune-modulatory and anti-inflammatory effects of these compounds as well as their potential properties of intestinal absorption and blood-brain barrier (BBB) permeability. We used peripheral blood mononuclear cells (PBMC) known to express the CB2 receptor. We observed that test compounds, CB13, CB82 and CB91 reduced PBMC proliferation. The anti-proliferative effect of CB13 and CB91 was partially mediated by the CB2 receptor. These compounds blocked the cells cycle and CB91 reduced T cell activation. CB82 and CB91 down-regulated the expression of phosphorylated proteins like NF-κB, ERK, Akt and the enzyme Cox-2, CB91 blocked the expression of the CB2 receptor and its inhibitory effect was CB2 receptor mediated. We also investigated CB91 properties of intestinal absorption and BBB permeability in order to suggest its potential efficacy on the infiltrating auto-reactive lymphocytes at the level of the central nervous system. For this purpose, CB91 was tested in drug-permeability assays on Caco-2 cells to evaluate its oral bioavailability and on MDCKII-hMDR1 cells to estimate its BBB permeability. The results indicated that this compound possesses medium level of intestinal absorption and BBB permeability. Our data suggest that CB91, modulating the immune response by CB2 receptor mediated mechanism and showing medium level of intestinal absorption and BBB permeability, might be developed as a potential orally delivered drug and might find potential application in pathologies like multiple sclerosis.
    Journal of Neuroimmune Pharmacology 10/2013; 8(5). DOI:10.1007/s11481-013-9494-0 · 3.17 Impact Factor
Show more

Similar Publications